US stock futures flat after Wall St drops on Trump tariffs, soft jobs data
LONDON - IXICO plc (AIM: IXI), the AI-powered medical imaging analytics company specializing in neuroscience, announced today that its revenues for the first six months ending March 31, 2025, have increased by 26% compared to the same period last year. The company is expected to report revenues of £3.2 million, up from £2.5 million in the prior year, aligning with or potentially exceeding its financial guidance.
The company’s order book stood at £13.1 million as of March 31, 2025, showing a slight increase from £12.7 million in the first half of the previous year. This includes new projects related to Alzheimer’s Disease research. Additionally, IXICO reported a robust cash balance of £5.0 million, a significant rise from £2.5 million, and remains debt-free following a capital raise earlier in the year.
IXICO also noted a reduced loss before interest, tax, depreciation, and amortisation, which is expected to be £0.7 million compared to a £1.3 million loss in the first half of 2024.
The company has been actively investing in expanding its operational services across the US time zone and appointing key roles, both commercial and operational, to enhance its visibility and attractiveness in this crucial market. Furthermore, IXICO is differentiating its imaging biomarker analysis pipelines for Alzheimer’s and Parkinson’s diseases, aiming to secure more contracts in these areas in the second half of 2025 and into 2026.
The company’s CEO, Bram Goorden, expressed satisfaction with the new global capabilities, talent, and innovation IXICO has added, leading to new client wins and building on the strong financial performance at the end of 2024. Goorden emphasized the company’s growing position in neurodegenerative disease research and the potential for accelerated market impact due to IXICO’s differentiated technology platform.
IXICO’s interim results for the first half of 2025 will be released on May 20, 2025. This announcement includes inside information now considered to be in the public domain. The information is based on a press release statement from IXICO plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.